Table 1—

Baseline characteristics of subjects randomly allocated to receive either magnesium chloride 2.5 g daily (MgCl2 group) or placebo (control group) for 16 weeks

MgCl2 group (n = 32)
Control group (n = 31)
Baseline*EndBaseline*End
Age (years)59.7 ± 8.354.1 ± 9.6
Time since diagnosis of diabetes (years)8.8 ± 4.99.4 ± 5.5
BMI (kg/m2)27.6 ± 9.127.7 ± 9.628.6 ± 4.228.9 ± 4.7
Weight (kg)72.9 ± 10.773.1 ± 10.469.3 ± 10.169.6 ± 9.9
Waist-to-hip ratio0.98 ± 0.060.98 ± 0.070.96 ± 0.040.96 ± 0.06
Systolic blood pressure (mmHg)148.3 ± 32.3140.2 ± 28.1138.1 ± 25.6135 ± 19.6
Diastolic blood pressure (mmHg)86.3 ± 17.082.7 ± 16.480.5 ± 14.679.1 ± 13.5
Fasting glucose (mmol/l)12.8 ± 5.68.0 ± 2.414.2 ± 3.910.3 ± 2.1§
HbA1c (%)11.5 ± 4.18.0 ± 2.411.8 ± 4.410.1 ± 3.3§
Fasting insulin (mmol/l)47.4 ± 30.067.8 ± 3948.6 ± 34.875.6 ± 33.0§
HOMA-IR index4.3 ± 1.23.8 ± 1.14.7 ± 1.55.0 ± 1.3
Total cholesterol (mmol/l)6.8 ± 1.76.4 ± 1.97.1 ± 1.47.0 ± 1.7
HDL cholesterol (mmol/l)0.9 ± 0.20.9 ± 0.10.8 ± 0.10.8 ± 0.1
LDL cholesterol (mmol/l)4.8 ± 1.64.7 ± 1.84.9 ± 2.04.8 ± 2.2
Triglycerides (mmol/l)2.4 ± 1.42.3 ± 1.52.5 ± 1.12.5 ± 1.6
Magnesium (mmol/l)0.64 ± 0.120.74 ± 0.100.65 ± 0.090.65 ± 0.07§
Calcium (mmol/l)2.5 ± 0.42.5 ± 0.52.4 ± 0.42.4 ± 0.4
Calcium-to-magnesium ratio3.9 ± 3.33.4 ± 3.23.7 ± 3.43.7 ± 3.5
  • Data are means ± SD.

  • *

    * At baseline, there were no significant differences for any parameters between both groups;

  • P < 0.05 from beginning to end for magnesium-supplemented subjects;

  • P < 0.05 from beginning to end for control subjects;

  • §

    § P < 0.05 at end of the study between magnesium-supplemented and control subjects.